Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Hangzhou Tigermed Consulting Co Ltd
3347Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, clinical development strategy, site management, subject recruitment, medical device/ in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. It also provides product market research, product marketing strategy, product finalization, product verification, registration strategy planning, marketing application, post-marketing supports, and product upgrade services. In addition, the company offers medical imaging, pharmacovigilance, medical translation, quality assurance, GMP consulting, central laboratories, functional services, EDC system, and call center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China. Address: Shengda Science Park, Hangzhou, China, 310051
Analytics
Zielpreis von Wall Street
378.88 HKDKGV
30.0413Dividendenrendite
3.25 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen 3347
Dividenden-Analyse 3347
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
2 JahreAusschüttungsquote 5-Jahres-Durchschnitt
19 %Verlauf der Dividende 3347
Bewertung der Aktie 3347
Finanzen 3347
Ergebnisse | 2019 | Dynamik |